{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:40Z","timestamp":1786984360640,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajpc.2025.101352","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:45:58Z","timestamp":1763635558000},"page":"101352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted APOC3 antisense oligonucleotide"],"prefix":"10.1016","volume":"24","author":[{"given":"Archna","family":"Bajaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Karwatowska-Prokopczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth J.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2025.101352_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atheroscler Suppl"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101352_bib0002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MED.0000000000000903","article-title":"An overview of persistent chylomicronemia: much more than meets the eye","volume":"32","author":"Larouche","year":"2025","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101352_bib0003","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","article-title":"Familial chylomicronemia syndrome: an expert opinion statement from the National Lipid Association","volume":"19","author":"Javed","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101352_bib0004","first-page":"723","article-title":"Recognition and management of persistent chylomicronemia: a Joint Expert Clinical Consensus by the National Lipid Association and the American Society for Preventive Cardiology","volume":"19","author":"Saadatagah","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"15","key":"10.1016\/j.ajpc.2025.101352_bib0005","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.3390\/jcm11154311","article-title":"Identifying patients with familial chylomicronemia syndrome using FCS score-based data mining methods","volume":"11","author":"Nemeth","year":"2022","journal-title":"J Clin Med"},{"issue":"19","key":"10.1016\/j.ajpc.2025.101352_bib0006","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1177\/2047487319888054","article-title":"Prevalence of familial chylomicronemia syndrome in a quaternary care center","volume":"27","author":"Pallazola","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101352_bib0007","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update","volume":"48","author":"Scherer","year":"2014","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101352_bib0008","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/metabo13050621","article-title":"Severe hypertriglyceridaemia and chylomicronaemia syndrome-causes, clinical presentation, and therapeutic options","volume":"13","author":"Bashir","year":"2023","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101352_bib0009","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","article-title":"Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association","volume":"14","author":"Brown","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101352_bib0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacl.2024.09.008","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","volume":"19","author":"Hegele","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2025.101352_bib0011","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\"","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2025.101352_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117476","article-title":"Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS)","volume":"391","author":"Bashir","year":"2024","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101352_bib0013","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study","volume":"12","author":"Blom","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101352_bib0014","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101352_bib0015","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101352_bib0016","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ajpc.2025.101352_bib0017","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101352_bib0018","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ajpc.2025.101352_bib0019","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101352_bib0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.101352_bib0021","unstructured":"Almac Pharma Services Ireland Ltd. Waylivra summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/waylivra-epar-product-information_en.pdf, 2019 (accessed 18 December 2024)."},{"key":"10.1016\/j.ajpc.2025.101352_bib0022","unstructured":"Business Wire. WAYLIVRA\u00ae (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England. https:\/\/www.businesswire.com\/news\/home\/20200918005029\/en\/, 2020 (accessed 18 December 2024)."},{"key":"10.1016\/j.ajpc.2025.101352_bib0023","unstructured":"PTC Therapeutics. PTC Therapeutics announces Waylivra\u2122 approval in Brazil as first treatment for familial chylomicronemia syndrome. https:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-announces-waylivratm-approval-brazil-first, 2021 (accessed 18 December 2024)."},{"key":"10.1016\/j.ajpc.2025.101352_bib0024","unstructured":"PTC Therapeutics Chile S.P.A. Folleto de informaci\u00f3n al profesional Waylivra. https:\/\/www.ispch.gob.cl\/wp-content\/uploads\/2023\/09\/F-27740.pdf, 2022 (accessed 18 December 2024)."},{"key":"10.1016\/j.ajpc.2025.101352_bib0025","unstructured":"Ionis Pharmaceuticals Inc. TRYNGOLZA (olezarsen) injection, for subcutaneous use. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218614s000lbl.pdf, 2024 (accessed 24 December 2024)."},{"key":"10.1016\/j.ajpc.2025.101352_bib0026","unstructured":"Ionis Ireland Limited. Tryngolza summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tryngolza#product-info, 2025 (accessed 17 October 2025)."},{"issue":"19","key":"10.1016\/j.ajpc.2025.101352_bib0027","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1056\/NEJMe2402653","article-title":"Shooting the messenger to treat hypertriglyceridemia","volume":"390","author":"Watts","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101352_bib0028","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J Intern Med"},{"issue":"10","key":"10.1016\/j.ajpc.2025.101352_bib0029","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.21037\/tp-22-488","article-title":"Familial chylomicronemia syndrome: importance of diagnostic vigilance","volume":"11","author":"Ueda","year":"2022","journal-title":"Transl Pediatr"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101352_bib0030","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","article-title":"The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study","volume":"12","author":"Davidson","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.ajpc.2025.101352_bib0031","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1210\/js.2019-00214","article-title":"Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles","volume":"3","author":"O'Dea","year":"2019","journal-title":"J Endocr Soc"},{"issue":"12","key":"10.1016\/j.ajpc.2025.101352_bib0032","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1161\/ATVBAHA.119.313401","article-title":"Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes","volume":"39","author":"D'Erasmo","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101352_bib0033","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jacl.2016.03.048","article-title":"Acute pancreatitis is highly prevalent and complications can be fatal in patients with familial chylomicronemia: results from a survey of lipidologist","volume":"10","author":"Gaudet","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2025.101352_bib0034","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","article-title":"Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia","volume":"283","author":"Paquette","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101352_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s41687-021-00347-5","article-title":"Development of a novel PRO instrument for use in familial chylomicronemia syndrome","volume":"5","author":"Davidson","year":"2021","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101352_bib0036","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101352_bib0037","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1573403X14666180123165542","article-title":"Hypertriglyceridemia - common causes, prevention and treatment strategies","volume":"14","author":"Rygiel","year":"2018","journal-title":"Curr Cardiol Rev"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101352_bib0038","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/17512433.2018.1480368","article-title":"Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome","volume":"11","author":"Chaudhry","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ajpc.2025.101352_bib0039","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosissup.2018.04.173","article-title":"A simple clinical diagnosis scoring system allowing to identify familial form of chylomicronemia syndrome","volume":"32","author":"Brisson","year":"2018","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.ajpc.2025.101352_bib0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clinbiochem.2023.02.002","article-title":"Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity","volume":"114","author":"Brisson","year":"2023","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ajpc.2025.101352_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.07.008","article-title":"Brief communication: strong concordance of the North American Familial Chylomicronemia Syndrome score with a positive genetic diagnosis in patients from the Balance study","author":"Brown","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101352_bib0042","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S2468-1253(16)30106-6","article-title":"Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer","volume":"1","author":"Hart","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101352_bib0043","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/clinem\/dgae613","article-title":"Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome","volume":"110","author":"Spagnuolo","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5908","key":"10.1016\/j.ajpc.2025.101352_bib0044","first-page":"1702","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science (1979)"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101352_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101352_bib0046","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/ATVBAHA.122.317966","article-title":"Broadening the scope of dyslipidemia therapy by targeting APOC3 (apolipoprotein C3) and ANGPTL3 (angiopoietin-like protein 3)","volume":"43","author":"Ginsberg","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101352_bib0047","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1172\/JCI109710","article-title":"Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat","volume":"65","author":"Shelburne","year":"1980","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.ajpc.2025.101352_bib0048","doi-asserted-by":"crossref","first-page":"8303","DOI":"10.1016\/S0021-9258(19)70647-4","article-title":"Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins","volume":"255","author":"Windler","year":"1980","journal-title":"J Biol Chem"},{"issue":"24","key":"10.1016\/j.ajpc.2025.101352_bib0049","doi-asserted-by":"crossref","first-page":"14642","DOI":"10.1016\/S0021-9258(18)33329-5","article-title":"The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat","volume":"257","author":"Quarfordt","year":"1982","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101352_bib0050","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0022-2275(20)34342-X","article-title":"Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver","volume":"26","author":"Windler","year":"1985","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101352_bib0051","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacl.2024.12.018","article-title":"Differential effects of volanesorsen on apoC-III, triglycerides and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteria","volume":"19","author":"Tsimikas","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101352_bib0052","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17446651.2024.2365787","article-title":"Etiology and emerging treatments for familial chylomicronemia syndrome","volume":"19","author":"Spagnuolo","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101352_bib0053","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ajpc.2025.101352_bib0054","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ajpc.2025.101352_bib0055","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4721357","article-title":"Management of hypertriglyceridemia induced acute pancreatitis","volume":"2018","author":"Garg","year":"2018","journal-title":"Biomed Res Int"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101352_bib0056","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1053\/j.gastro.2018.12.041","article-title":"Organ failure due to systemic injury in acute pancreatitis","volume":"156","author":"Garg","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101352_bib0057","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1053\/j.gastro.2018.01.032","article-title":"American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on initial management of acute pancreatitis","volume":"154","author":"Crockett","year":"2018","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1016\/j.ajpc.2025.101352_bib0058","first-page":"e1","article-title":"IAP\/APA evidence-based guidelines for the management of acute pancreatitis","volume":"13","year":"2013","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101352_bib0059","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12944-022-01631-z","article-title":"Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia","volume":"21","author":"Paragh","year":"2022","journal-title":"Lipids Health Dis"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101352_bib0060","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(25)00028-2","article-title":"Futility of plasmapheresis, insulin in normoglycaemic individuals, or heparin in the treatment of hypertriglyceridaemia-induced acute pancreatitis","volume":"13","author":"Syed-Abdul","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajpc.2025.101352_bib0061","unstructured":"Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals announces acceptance of New Drug Application by U.S. FDA of plozasiran for the treatment of familial chylomicronemia syndrome. https:\/\/ir.arrowheadpharma.com\/news-releases\/news-release-details\/arrowhead-pharmaceuticals-announces-acceptance-new-drug, 2025 (accessed 13 October 2025)."},{"key":"10.1016\/j.ajpc.2025.101352_bib0062","unstructured":"ClinicalTrials.gov. Study of RN0361in adult healthy subjects and adult hypertriglyceridemic subjects. https:\/\/clinicaltrials.gov\/study\/NCT06471543, 2025 (accessed 13 October 2025)."},{"key":"10.1016\/j.ajpc.2025.101352_bib0063","unstructured":"ClinicalTrials.gov. CS-121 APOC3 base editing in FCS. https:\/\/clinicaltrials.gov\/study\/NCT07176923, 2025 (accessed 13 October 2025)."},{"key":"10.1016\/j.ajpc.2025.101352_bib0064","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1476-511X-9-58","article-title":"Lipid profile in consecutive pregnancies","volume":"9","author":"Mankuta","year":"2010","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ajpc.2025.101352_bib0065","unstructured":"Food and Drug Administration. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. https:\/\/www.fda.gov\/media\/116737\/download, 2009 (accessed 30 December 2024)."}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725004271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725004271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:13:21Z","timestamp":1768482801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667725004271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":65,"alternative-id":["S2666667725004271"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101352","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted APOC3 antisense oligonucleotide","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101352"}}